Precirix has raised €80 million ($88 million) in a second-round financing that will be used to advance multiple radiopharmaceutical candidates for cancer through clinical development.
Belgium's Ministry of Health has paused dosing of people under the age of 41 with Johnson & Johnson's one-shot COVID-19 vaccine, following the death of a woman from what appeared to be